Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
about
The EMPA-REG outcome study: critical appraisal and potential clinical implicationsNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsIncreased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewSodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.Anti-high Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lpr Lupus-Prone Mice.Dapagliflozin in patients with type 2 diabetes mellitus.Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy.Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Functional expression of sodium-glucose transporters in cancer.Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells.Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes.Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.Diabetic nephropathy: landmark clinical trials and tribulations.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Recent advances in glucose-lowering treatment to reduce diabetic kidney disease.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic miceDapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization.The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.Glucosuria and all-cause mortality among general screening participants.
P2860
Q26748742-C0C53C3A-05B1-4229-B54E-383186990C63Q26777994-7971E24F-93C7-43A0-ACEA-DED47905B16CQ26864336-F7D771CB-88D4-4BCC-A921-0E2C0077C305Q28072765-E7E2A884-1B4E-4723-9BB5-9275BC4B23CBQ28072939-6489ADC9-8BA9-4C39-98BA-E3ED2AB850D3Q28079134-09CA2340-729A-45EB-8B98-87A36F3C1341Q33619161-3A1AA217-8096-4A3E-9F70-5B46232A9791Q33802812-28B0E24A-7D68-4778-9577-45945BA9FA34Q35064363-524B5D57-D51E-48AA-B804-95477F9545E9Q35196985-A547DBA0-3E6E-44E9-8CB0-81CE452398F8Q35887931-94D65BFB-E200-4069-972E-D18C9C1B83BAQ35909986-37A58D10-0D98-4389-B580-190E2AF5A569Q35964702-C10B6B51-BB12-4738-BA6C-79561F90B3E1Q36004330-192BDDD5-6F90-4716-BA2A-577436518DF9Q36179371-C3E075BC-0F2B-4EB0-89F5-C5006FE7D4ACQ36851156-B891768B-9B2E-4058-83C0-F4872A6A03A6Q36937697-7E580770-D4A5-4531-819D-0D53D682B7D8Q37559899-CB7458BC-A678-432F-BDB9-F0F8B71A58D9Q37571861-56505B32-4C5D-4A86-A986-2F40FAC8CFD5Q37685967-3AC35D9B-BB1F-4EFD-A344-47759061C773Q38250445-93CF598E-B00B-4DF8-B838-5309293EC2C7Q38338539-5AA37B89-ECD9-40EC-BD05-5770012FEB79Q38429845-7B2F8FD8-F3A9-4653-AE7A-ECD42228579EQ38442040-84AF1C4B-7C03-4C22-8A95-3DC928F03A89Q38635763-283B6BA4-9AB5-439D-9710-624B0E4052FDQ38698841-98663BF5-715E-4402-80C8-D8F1047EA6BCQ38715153-493C8D5B-D7AF-4B41-8376-075F50BBE776Q38775305-055644D6-0DB7-47B1-90A1-2276CCF544E7Q38906470-3027F21B-1AC3-4B39-8849-5D45358FAB07Q38961637-616D02DD-007D-4302-AF03-65457A4EA927Q39017610-49907B94-1E1D-4E0C-94C9-0BD7AD91E09BQ39290337-6E95CEDF-D57C-4172-ADE4-8A58FE154BEAQ41623607-57BF08B2-7735-442C-8A08-0C3B112F78CBQ42006157-0D01F166-57F7-46C2-9E71-2C5C032C8F50Q42329981-0865BFFF-2A00-43C0-90D1-63ECD0F9A7E5Q47137994-4B29658F-7A25-4A6D-8392-C072ADFD9C31Q48141985-B9BFB06B-EE57-47C0-9C1D-4013C46314D4Q49617047-EA14FC34-450C-46E1-AC1F-16F680E110BDQ49715387-F59DE7DC-13C6-46FE-B9E5-A209E395D78EQ50057769-63CE55EC-096F-4413-AD9A-17F8160A6DBE
P2860
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@ast
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@en
type
label
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@ast
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@en
prefLabel
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@ast
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@en
P2093
P2860
P1433
P1476
Long-term treatment with the s ...... tic nephropathy in db/db mice.
@en
P2093
Atsuko Nakatsuka
Chikage Sato Horiguchi
Daisuke Ogawa
Hirofumi Makino
Hiromi Tachibana
Hiroshi Yamada
Jun Eguchi
Kohji Takei
Naoko Nishii
Naoto Terami
P2860
P304
P356
10.1371/JOURNAL.PONE.0100777
P407
P50
P577
2014-06-24T00:00:00Z